Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Age at disability milestones in multiple sclerosis.

Christian Confavreux1, Sandra Vukusic

  • 1The European Database for Multiple Sclerosis (EDMUS) Coordinating Center and Service de Neurologie A, INSERM U 433, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France. christian.confavreux@chu-lyon.fr

Brain : a Journal of Neurology
|January 18, 2006
PubMed
Summary

Multiple sclerosis prognosis is age-dependent, with younger onset leading to earlier disability milestones. Disease course and initial symptoms had less impact on the age patients reach disability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.

Brain : a journal of neurology·2026
Same author

Updated French OFSEP recommendations for multiple sclerosis MRI: alignment with the 2024 McDonald criteria.

Journal of neuroradiology = Journal de neuroradiologie·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Neurology·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026

Area of Science:

  • Neurology
  • Clinical Neuroscience
  • Epidemiology

Background:

  • Prognosis in multiple sclerosis (MS) typically focuses on time to disability milestones.
  • The age at which MS patients reach these milestones remains under-investigated.
  • Understanding age-related factors in MS progression is crucial for patient management.

Purpose of the Study:

  • To test the hypothesis that MS prognosis depends on patient age and initial disease course.
  • To determine the median age of reaching specific irreversible disability milestones in MS.
  • To identify early clinical factors influencing the age of disability progression.

Main Methods:

  • Kaplan-Meier analyses were used to estimate median ages at disability milestones.
  • Kurtzke Disability Status Scale (DSS) scores 4, 6, and 7 were used as benchmarks.

Related Experiment Videos

  • Univariate and multivariate Cox models analyzed the influence of clinical variables, including age at onset and initial disease course.

    • Main Results:

    • Median ages for reaching DSS 4, 6, and 7 were 44.3, 54.7, and 63.1 years, respectively.
    • Prognosis was similar for exacerbating-remitting and progressive MS courses.
    • Younger age at clinical onset was the strongest predictor of younger age at disability milestones; females reached milestones later than males.

    Conclusions:

    • Multiple sclerosis prognosis is significantly age-dependent.
    • The initial course of MS (relapsing-remitting or progressive) has a limited impact on the age of disability milestones.
    • Accelerated aging mechanisms may contribute to MS progression alongside inflammation and neurodegeneration.